BIIB34:BVMF
Biogen Inc BDR
၁၈၆.၀၁ R$
၀.၀၀%
(၀.၀၀) 1D
အောက် ၉, GMT-၃ ၁၆:၅၆:၀၀ · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Open
၁၈၆.၀၁ R$
High
၁၈၆.၀၁ R$
Low
၁၈၆.၀၁ R$
Mkt. cap
ဋေ ၃.၃၃ ထ
Avg. vol.
၇.၀၀
Volume
၁.၀၀
52-wk high
၁၉၁.၀၀ R$
52-wk low
၁၂၈.၆၉ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
Open
၁၈၆.၀၁ R$
High
၁၈၆.၀၁ R$
Low
၁၈၆.၀၁ R$
Mkt. cap
ဋေ ၃.၃၃ ထ
Avg. vol.
၇.၀၀
Volume
၁.၀၀
52-wk high
၁၉၁.၀၀ R$
52-wk low
၁၂၈.၆၉ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
News stories
From web sources and news partners
The Boston Globe
·
ပြီးခဲ့သည့် ၅၁ မိနစ်
Local life sciences scene ‘can’t just rest on our laurels,’ Biogen CEO warns
CNBC
·
ပြီးခဲ့သည့် ၅၃ မိနစ်
Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၄ မိနစ်
BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300
Investing.com
·
ပြီးခဲ့သည့် ၁ နာရီ
JPMorgan gets bullish on Biogen ahead of 2027 catalysts
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees၇.၅ ထောင်
Founded၁၉၇၈
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitebiogen.com